Mati Therapeutics Inc.
๐บ๐ธUnited States
A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma
Phase 2
Withdrawn
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- Drug: Latanoprost-PPDS
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Mati Therapeutics Inc.
- Registration Number
- NCT00855517
Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma
Phase 2
Completed
- Conditions
- Ocular HypertensionGlaucoma
- Interventions
- Drug: artificial tears preserved with Benzalkonium Chloride
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Mati Therapeutics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00845299
A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Mati Therapeutics Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00821002
A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma
Phase 2
Completed
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- Drug: Latanoprost-PPDS
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Mati Therapeutics Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT00820300
Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Phase 2
Completed
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- Drug: Latanoprost-PPDS
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Mati Therapeutics Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00650702
ยฉ Copyright 2025. All Rights Reserved by MedPath